Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aroa Biosurgery Limited (ARX.AX)
Auckland, NZ
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +3.33% | +16.98% | -3.88% | -9.49% | -16.22% | +36.26% | -34.04% | -48.33% | -54.07% | -54.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+19.9% ★ Q1'26: +182.5% (vs Q3'24)
-
EPS growth Medical - Devices: +28.5%+212.9% ★ Q1'26: +425.0% (vs Q3'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%+7.7% Q1'26: +9.7% (vs Q3'24)
-
EBIT margin Medical - Devices: +6.2%+4.7% Q1'26: +11.4% (vs Q3'24)
-
ROIC Medical - Devices: +3.3%+6.7% ★ Q1'26: +33.7% (vs Q3'24)
-
Share dilution Medical - Devices: 0.0%+5.4% Q1'26: +4.3% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.59× ★ Q1'26: 0.16× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 3 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.51M
est: 29.96M (-31.5%)
|
36.88M
est: 36.63M (+0.7%)
|
59.31M
est: 59.34M (-0.1%)
|
63.36M
est: 62.42M (+1.5%)
|
76.97M
est: 75.06M (+2.5%)
|
86.58M
86.06M – 86.92M
+15.4% YoY
|
97.20M
95.27M – 98.74M
+12.3% YoY
|
111.86M
109.64M – 113.63M
+15.1% YoY
|
125.32M
122.84M – 127.31M
+12.0% YoY
|
| EBITDA |
-7.05M
est: -3.04M (-132.3%)
|
-3.75M
est: -3.71M (-1.0%)
|
683.9K
est: -6.01M (+111.4%)
|
-6.78M
est: 19.00M (-135.7%)
|
2.65M
est: 22.85M (-88.4%)
|
26.36M
26.20M – 26.46M
+15.4% YoY
|
29.59M
29.00M – 30.06M
+12.3% YoY
|
34.05M
33.38M – 34.59M
+15.1% YoY
|
38.15M
37.40M – 38.76M
+12.0% YoY
|
| EBIT |
-9.17M
est: -5.13M (-78.7%)
|
-6.70M
est: -6.28M (-6.8%)
|
-2.91M
est: -10.17M (+71.4%)
|
-10.72M
est: 17.72M (-160.5%)
|
-1.85M
est: 21.31M (-108.7%)
|
24.58M
24.43M – 24.67M
+15.4% YoY
|
27.59M
27.05M – 28.03M
+12.3% YoY
|
31.75M
31.13M – 32.26M
+15.1% YoY
|
35.58M
34.87M – 36.14M
+12.0% YoY
|
| Net Income |
-17.63M
est: -7.29M (-141.8%)
|
-7.79M
est: -5.91M (-31.9%)
|
-370.7K
est: -1.78M (+79.2%)
|
-9.75M
est: -2.56M (-280.9%)
|
-3.47M
est: -1.24M (-180.3%)
|
3.54M
3.53M – 3.55M
+386.4% YoY
|
7.96M
2.82M – 9.88M
+124.6% YoY
|
13.64M
6.20M – 19.15M
+71.5% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
19.98M
est: 25.12M (-20.5%)
|
28.54M
est: 30.72M (-7.1%)
|
44.66M
est: 49.75M (-10.2%)
|
57.01M
est: 52.34M (+8.9%)
|
60.93M
est: 62.93M (-3.2%)
|
72.60M
72.16M – 72.87M
+15.4% YoY
|
81.50M
79.88M – 82.79M
+12.3% YoY
|
93.79M
91.93M – 95.27M
+15.1% YoY
|
105.07M
103.00M – 106.74M
+12.0% YoY
|
| EPS |
-0.06
est: -0.02 (-177.6%)
|
-0.02
est: -0.02 (-33.1%)
|
0.00
est: -0.01 (+78.6%)
|
-0.03
est: -0.01 (-286.7%)
|
-0.01
est: 0.00 (-135.6%)
|
0.01
0.01 – 0.01
+341.9% YoY
|
0.02
0.01 – 0.03
+101.9% YoY
|
0.03
0.02 – 0.06
+65.8% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian Ward | Founder, Chief Executive Officer, MD & Executive Director | 547.8K | — |
| James Agnew | Chief Financial Officer & Joint Company Secretary | 312.8K | male |
| Frazer Murray | Director of Global Marketing & Strategy | — | male |
| Neetha Alex-Kumar | General Counsel | — | female |
| Rod Stanley | Chief Operating Officer | — | male |
| Tracy Weimar | Joint Company Secretary | — | female |
| Adam Young | Vice President of Medical Affairs | — | male |
| Yasmin Winchester | Chief of Technical Operations | — | female |
| Barnaby May | Chief Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARX.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
